Teuza: The Alfred Mann Buyback, the Capital Reduction, and the Real Cost to Cash
The Alfred Mann settlement has turned Teuza from an ownership-dispute story into a capital-allocation test: a NIS 9.2 million buyback, a court-required capital reduction because there are no distributable profits, and a liquidity squeeze just as an estimated $2.8 million from the Bioness case is still waiting for approval.
No Longer Legal Noise, but a Capital Allocation Decision
The main article argued that Teuza still has value inside the portfolio, but that the real test has already moved to the cash layer and to how much of that value is actually accessible at the listed-company level. This follow-up isolates the Alfred Mann thread because once the dispute became a signed settlement with a price tag, a payment schedule, and a capital-reduction filing, it stopped being background legal noise. It became a capital allocation decision that hits cash directly.
The settlement signed on February 4, 2026 says Teuza will buy 23,957,192 shares for NIS 9.2 million. On March 24, 2026 the general meeting already approved the deal, but completion still depends on court approval for a capital reduction. In parallel, the management company undertook to pay the trustees another NIS 700 thousand, of which NIS 500 thousand was already paid within two days and will not be refunded even if the arrangement is not completed. That is the heart of the story. The cost of this event does not begin and end with the question of who won the dispute. It begins with the question of which cash pocket will fund the settlement.
What makes this especially important is the timing. Teuza ended 2025 with just $2.160 million of cash and cash equivalents, down 28.5% from year-end 2024, while explicitly stating that this cash is meant to support portfolio companies, make new investments, and cover obligations. The Alfred Mann settlement is therefore not just cleanup. It directly competes for the same liquidity buffer.
| Item | What was set | Why it matters |
|---|---|---|
| Settlement agreement | Teuza will buy 23,957,192 shares for NIS 9.2 million | The legal dispute became a concrete company-level cash use |
| Approvals already obtained | Board approval and shareholder approval on March 24, 2026 | The key remaining risk has moved to court approval and execution |
| What is still missing | Court approval for capital reduction | This is not a routine buyback out of surplus profits |
| Management company payment | NIS 700 thousand, of which NIS 500 thousand has already been paid and is non-refundable | At the wider event level, real cash has already gone out |
| Potential offset | Teuza estimates its share of the Bioness settlement at about $2.8 million | That matters a lot, but it is still subject to Delaware court approval and legal-fee sizing |
This Is Not a Normal Buyback
Teuza explicitly wrote that as of December 31, 2025 it had no distributable profits. That is why the settlement is not being executed as a standard buyback out of comfortable surplus. Instead, it required a court filing for a capital reduction under Section 303 of the Companies Law. The February 26, 2026 filing says so plainly: the company asked to approve a NIS 9.2 million self-purchase not out of profits, and it also disclosed equity of NIS 45.5 million as of June 30, 2025 as the basis for the request. That means the buyback equals about 20.2% of the equity base Teuza itself presented to the court.
That makes the capital reduction more than a legal technicality. It is part of the economics of the transaction. In the filing published on February 26, 2026, the company's creditors were invited to approach the court or object to the request within 30 days.
The per-share math is just as sharp. NIS 9.2 million divided by 23,957,192 shares implies about 38.4 agorot per share. Against the last share price of 30 agorot on April 3, 2026, that is a premium of about 28%. On the other hand, if the court approves the transaction and the company buys the full block, the share count would fall from about 113.94 million shares to about 89.98 million, a reduction of roughly 21.0% of the current share capital.
This is the strongest counter-read to the cash-pressure argument: if the company is cancelling about 21% of its share capital, one can argue that the cash premium is a fair price for cleaning up the cap table and improving the economics per share. That is a legitimate argument, but it is incomplete. According to note 10(d), the disputed shares had already been frozen since March 2022, remained registered in the deceased shareholder's name, and neither the plaintiffs nor the management company could vote them until judgment. So Teuza is not paying to neutralize an actively voting hostile block. It is paying to close a long-running dispute, reduce the share count, and turn an immobilized block into a cancelled block. The immediate benefit is more economic and accounting-driven than instantly governance-changing.
The Real Cost to Cash
If we strip away the legal wrapper for a moment, 2025 shows why this event is heavy for liquidity. Teuza ended the year with $2.160 million of cash and cash equivalents, down from $3.021 million at the end of 2024. During 2025 it used $517 thousand in operating cash flow and another $348 thousand in investing cash flow, even after receiving $56 thousand of interest and a $752 thousand dividend from Signet. In other words, even in a year when cash came in from a portfolio holding, the cash buffer still shrank.
This is the most important fact in the continuation thesis. Teuza is not sitting on a stable recurring operating cash engine. In 2025, total reported income was just $812 thousand, of which $752 thousand came from a dividend from a held company and $60 thousand from finance income. Against that, the company reported a loss of $1.248 million. The cash position is therefore not surplus. It is the raw material of the business model.
And the company leaves little room for interpretation about how that raw material is supposed to be used. In the directors' report, Teuza says that cash is intended for continued support and development of portfolio companies, new investments, and payment of obligations. So every shekel directed to the Alfred Mann buyback is a shekel that is no longer available for the very function through which Teuza is supposed to create future value.
This is also where it matters to separate the company-level cost from the wider event cost. At Teuza itself, the direct hit is NIS 9.2 million. At the wider settlement level, Teuza and the management company together are committed to NIS 9.9 million. It is important not to mix the pockets, because the extra NIS 700 thousand sits at the management-company layer rather than inside the public company. But it is equally important not to ignore it, because it is part of the real economic price of ending the dispute, and NIS 500 thousand of it has already become a sunk cost.
What Could Offset the Hit, and What Still Has Not Landed
The good news is that Teuza is not entering this move with no possible offset. In the Bioness class action, a settlement of about $8.9 million was reached for minority shareholders in November 2025, and Teuza estimates its own share at roughly $2.8 million. That number is larger than the cash balance with which it ended 2025. So if the money arrives in full and on a workable timetable, it could materially change the liquidity read.
The problem is that the money is still not there. Both the shareholders-meeting notice and note 10(c) make it explicit that there is no certainty around the final amount because it depends on the Delaware court's determination of legal fees and expenses, and that as of the report-signing date the court had not yet approved the settlement. So the Alfred Mann deal cannot be analyzed as if the Bioness proceeds have already funded it. On the local evidence base, this is still a grounded possibility, not cash in hand.
That is exactly why the payment schedule matters. The Alfred Mann settlement says half of the consideration is due within 90 days of signing and the other half within six months of signing. That is a relatively front-loaded schedule for an event that still depends on court approval for the capital reduction and, on the offsetting side of the balance sheet, on a separate Delaware approval to turn the estimated $2.8 million into an actual inflow. So the short-term market test is not whether the deal sounds rational in theory. It is whether Teuza receives the required approvals and the opposing cash inflow quickly enough to stop the event from turning legal pressure into liquidity pressure.
This is also where the positive case needs to be read carefully. If the move is approved and completed, it may indeed improve the economics per share. A roughly 21% block of share capital would disappear, a long-running dispute would close, and the listed company would be left with a cleaner cap table. But that improvement is not free. It is being bought at a premium to the last price, through a capital reduction, while the company itself says it has no distributable profits and that the existing cash balance is needed for portfolio support as well. In other words, this is not a move that creates value from thin air. It is a move that swaps one kind of friction, an ownership dispute, for another, a cash test.
The Bottom Line
The Alfred Mann settlement changes the right way to read Teuza. Until now, the company could still be framed mainly as a small venture portfolio with a messy ownership overhang. Now it is more accurate to frame it as a tiny holding company that chose to spend real cash to end a dispute, cancel about 21% of its share capital, and clean up the cap table. This is a capital decision, not just a legal one.
There is a real upside case here: if the arrangement is completed, the market will be left with fewer shares, less noise around the dispute, and perhaps also a material offset from the Bioness settlement. The less comfortable part is that this upside still leans on money that has not arrived, while the outgoing cash commitment is already clearly defined. So in the near term, the right read on Teuza does not run through whether the settlement sounds reasonable. It runs through two harder checkpoints: whether the court approves the capital reduction, and whether the Bioness settlement turns from an estimated $2.8 million into cash that is genuinely accessible at the parent layer.
The thesis now is simpler and harsher: the Alfred Mann deal may improve the math per share, but until proven otherwise, it eats cash first.
Disclosure: Deep TASE analyses are general informational, research, and commentary content only. They do not constitute investment advice, investment marketing, a recommendation, or an offer to buy, sell, or hold any security, and are not tailored to any reader's personal circumstances.
The author, site owner, or related parties may hold, buy, sell, or otherwise trade securities or financial instruments related to the companies discussed, before or after publication, without prior notice and without any obligation to update the analysis. Publication of an analysis should not be read as a statement that any position does or does not exist.
The analysis may contain errors, omissions, or information that changes after publication. Readers should review official filings and primary sources before making decisions.